Paternal Acitretin Exposure and the Risk of Miscarriage and Major Congenital Malformations

TAKE-HOME MESSAGE

• In this Danish cohort study, the rates of miscarriages and congenital malformations among pregnancies with preconception or first trimester paternal acitretin exposure were compared with those without exposure. Miscarriage occurred in 6% of exposed pregnancies versus 9% among unexposed (HR, 0.71). Major congenital malformations were identified in 4% of exposed pregnancies versus 4% of unexposed pregnancies (HR, 1.15).

• Based on these data, there does not appear to be any increased risk of miscarriage or congenital malformations among pregnancies with paternal acitretin exposure. This may assist dermatologists in counseling men on this medication.

– Margaret Hammond, MD

Abstract 

Acitretin is highly teratogenic when given to women before and during pregnancy, but data concerning paternal acitretin exposure and adverse pregnancy outcomes are limited.1,2 To support this, we conducted a nationwide register-based cohort study including all registered pregnancies in Denmark between 1997 and 2016. Information on registered pregnancies was obtained from the Medical Birth Registry and National Hospital Registry.3,4 Paternal acitretin exposure was identified from the National Prescription Registry holding information on all redeemed prescriptions in the country.5

Journal of the American Academy of Dermatology

Paternal Acitretin Exposure and the Risk of Miscarriage and Major Congenital Malformations: A Nationwide Register-Based Cohort Study

J Am Acad Dermatol 2020 Mar 16;[EPub Ahead of Print], M Noergaard, SS Clausen, JT Andersen 

Sent from my iPhone

Benjamin Hidalgo-Matlock
Skin Care Physicians of Costa Rica

Clinica Victoria en San Pedro: 4000-1054
Momentum Escazu: 2101-9574

Please excuse the shortness of this message, as it has been sent from
a mobile device.